Navigation Links
Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
Date:7/29/2008

ble programs. The most advanced compounds in development include VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and the octreotide implant for acromegaly.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
2. Indevus Announces Management Changes
3. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
4. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
5. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
6. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
7. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
8. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
9. Indevus Announces Allergan as New Partner for SANCTURA Brand
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
(Date:5/23/2013)...  Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., ... banking and therapeutics, announced today that StemCyte has become ... Indy car driven by James Jakes ... IndyCar 2013 season.   StemCyte, Inc. and Rahal ... of umbilical cord blood banking and its educational initiative ...
(Date:5/23/2013)... Virobay, Inc. today announced that their development ... important milestone, as Virobay has now initiated a Phase ... S inhibitor.   The first Phase 1 ... designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics ... "The initiation of this Phase 1 trial with ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... African-Americans in STEM industries, Black Data Processing Associates (BDPA), ... Day on June 8, 2013. This all-day event will ... arena, and learn the ins and outs from many ... to 3 p.m. at the New Jersey Institute of ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2
... to generate energy is a signifiant step closer following ... East Anglia (UEA). Published today by the leading ... Sciences (PNAS), the research demonstrates for the first ... enable bacterial cells to transfer electrical charge. The ...
... WASHINGTON, May 23, 2011The Annual Meeting of the American ... June 2, 2011, in New Orleans, Louisiana. Crystallography is ... in regular crystalline solids and in complicated molecules. The ... the structure of important materials are often calculated by ...
... (OTCQX: DATA), a technology and services company focused on ... announced the Company,s selection as a 2011 Crain,s Leading ... "Being once again recognized as an EDGE ... and its employees have to bringing a quality product ...
Cached Biology Technology:Discovery opens the door to electricity from microbes 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 2Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 3Sulfates in extreme places, DNA tied in knots and magnetic cooling at crystallography meeting 4DATATRAK Recognized as 2011 Crain's Leading EDGE Award Winner 2
(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... Investigators at Rollins School of Public Health at ... Institute of Technology, have received a $4 million ... Center at Emory University (Health and Exposome Research ... first exposome-based center grant awarded in the United ... by the National Institute of Environmental Health Sciences ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3
... is a strong candidate for involvement in premenstrual dysphoric ... flux in hormones during the menstrual cycle. In a ... National Academy of Sciences , Rockefeller University researchers detail ... of the gene increases anxiety, dampens curiosity and tweaks ...
... has long been a model system for studying and understanding ... that cause influenza, measles and rabies. More ... be genetically modified to serve as an anti-cancer agent, exercising ... and as a potent vaccine against HIV. ...
... , REDWOOD CITY, Calif. ... leader in fingerprint identity and authentication solutions, continues to ... and franchise owners.  The latest version of the popular ... U.are.U® fingerprint biometrics technology from DigitalPersona, will be unveiled ...
Cached Biology News:Research identifies gene with likely role in premenstrual disorder 2Research identifies gene with likely role in premenstrual disorder 3Researchers reveal 3-D structure of bullet-shaped virus with potential to fight cancer, HIV 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 2Digital Dining Customers Demand Fingerprint Biometrics in Point-of-Sale Technology 3
Immunogen: Synthetic peptide (KLH conjugated): L(506) S K S S S Q I R M S G L P A D N L A T(525) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
For quantitative determination of Aldolase in Serum (an indicator of muscle damage). Ready-to-use liquid stable reagent. Formulated to eliminate interference from pyruvates. Application sheets are ...
Biology Products: